Coya Therapeutics, Inc. (NASDAQ:COYA) Sees Large Growth in Short Interest

Coya Therapeutics, Inc. (NASDAQ:COYA) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 196,500 shares, a growth of 5.6% from the October 15th total of 186,100 shares. Based on an average daily volume of 77,200 shares, the days-to-cover ratio is currently 2.5 days. Currently, 1.4% of the shares of the stock are sold short.

Insider Buying and Selling

In related news, CEO Arun Swaminathan bought 5,000 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were purchased at an average cost of $7.34 per share, with a total value of $36,700.00. Following the completion of the purchase, the chief executive officer now owns 5,000 shares in the company, valued at approximately $36,700. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders bought 9,510 shares of company stock worth $69,615 in the last quarter. 9.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Coya Therapeutics

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in shares of Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after buying an additional 750,338 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Coya Therapeutics in the 2nd quarter valued at $101,000. GHP Investment Advisors Inc. bought a new stake in Coya Therapeutics during the third quarter worth about $169,000. Gilbert & Cook Inc. bought a new stake in Coya Therapeutics during the second quarter worth $61,000. Finally, Geode Capital Management LLC boosted its stake in Coya Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after purchasing an additional 4,485 shares during the last quarter. 39.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on COYA. Chardan Capital restated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research report on Thursday, November 7th. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, November 11th.

Coya Therapeutics Price Performance

Shares of NASDAQ COYA traded up $0.14 during mid-day trading on Tuesday, hitting $6.21. The company had a trading volume of 69,771 shares, compared to its average volume of 71,781. Coya Therapeutics has a 12 month low of $4.75 and a 12 month high of $10.69. The firm’s 50 day simple moving average is $7.12 and its two-hundred day simple moving average is $6.95. The stock has a market cap of $103.77 million, a price-to-earnings ratio of -9.35 and a beta of 0.46.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.15. Equities analysts forecast that Coya Therapeutics will post -1.15 earnings per share for the current year.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.